Project Grant R01CA302774
Award Date 8/18/25
Completion Date 7/31/30
Dollars Obligated $684K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Massachusetts, USA
Similar Awards
- This Project Grant, awarded by the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower), provides $195,240 to The General Hospital Corporation (doing business as Massachusetts General Hospital) to develop a single-cell assay for correlating genome, transcriptome, and dynamic behaviors of metastatic cancer cells in an in vivo mice model using laser particles. The project aims to: 1) Employ laser particles to correlate single-cell sequencing with real-time observations of cancer cell...
- This federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $231,413 to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), to reconstitute human testicular germ cell neoplasia in situ (GCNIS) in vitro using induced pluripotent stem cell-derived primordial germ cell-like cells and genetically engineered human testicular cancer cells. The goal is to establish in vitro models that recapitulate the...
- This Project Grant award of $654,197 was provided by the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) to The General Hospital Corporation (doing business as Massachusetts General Hospital) on April 8, 2025. The award will fund a 5-year research program to develop patient-derived xenograft (PDX) tumor models that represent the molecular heterogeneity of pancreatic ductal adenocarcinoma (PDAC). The research aims to define PDAC molecular subtypes responsive to...
- This federal Project Grant award of $2,855,619 from the National Cancer Institute's Cancer Detection and Diagnosis Research program (CFDA 93.394) is supporting the development of CAMPEX, an integrated platform for highly sensitive and precise molecular analysis of extracellular vesicles (EVs) to enable improved cancer detection and monitoring. The award aims to: 1) Enhance CAMPEX's analytical capabilities to enable high-throughput and comprehensive EV analysis, and 2) Rigorously evaluate the...
- This federal Project Grant award of $176,040 from the National Cancer Institute (CFDA 93.398 Cancer Research Manpower program) supports research at The General Hospital Corporation (doing business as Massachusetts General Hospital) to investigate the impact of aging on the function of conventional type 1 dendritic cells (cdc1s) and their influence on CD8+ T cell immunity in tumor microenvironments. The project aims to elucidate the mechanisms underlying the defective function of aged cdc1s and...
- This Project Grant award from the National Cancer Institute's Cancer Detection and Diagnosis Research program (CFDA 93.394) supports the development of GLISCAN, a multi-analyte, multi-mutation blood-based assay for rapid, sensitive molecular subtyping of gliomas. The $678,228 award to The General Hospital Corporation (doing business as Massachusetts General Hospital) will fund a multi-phase study to optimize, verify, and validate the GLISCAN assay, which aims to enable quantification of tumor...
- This federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $620,820.00 to The General Hospital Corporation (doing business as Massachusetts General Hospital) to investigate the role of the transcription factor CREB5 in driving immune therapy resistance in cancer. The research aims to: 1) understand the molecular mechanisms governing CREB5 regulation and transcription, 2) identify CREB5-interacting proteins that drive collagen matrix...
- This $662,516 Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research conducted by The General Hospital Corporation (doing business as Massachusetts General Hospital) to evaluate how fractionated radiation affects the tumor microenvironment and passive drug delivery in mouse and patient-derived models of locally advanced head and neck squamous cell carcinoma and anaplastic thyroid cancer. The research aims to quantify the impact of local...
- This Project Grant award, provided by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research), aims to develop a targeted therapy for the treatment of metastatic castration-resistant prostate cancer (mCRPC). The $571,271 award, granted on April 15, 2025, will fund research to create a drug conjugate that combines the PSMA-targeting small molecule PSMA-617 with the microtubule inhibitor monomethyl auristatin E (MMAE) and a custom macrocyclic linker. This novel targeted therapy...
- This federal Project Grant award, funded by the National Cancer Institute (CFDA 93.398 Cancer Research Manpower), supports research to develop new strategies for CAR-T cell therapies to overcome the cancer cell glycocalyx barrier in solid tumors. The $176,040 grant, awarded to The General Hospital Corporation (doing business as Massachusetts General Hospital), aims to: 1) engineer CAR-T cells to strengthen the immune synapse by enhancing binding to the cancer cell glycocalyx, and 2) develop...